Japan's Ministry of Health has approved Sanofi's Wayrilz (rilzabrutinib), a novel oral BTK inhibitor, for treating persistent or chronic immune thrombocytopenia (ITP) in patients unresponsive or intolerant to other treatments. The approval is based on the LUNA 3 phase 3 study, which showed Wayrilz significantly improved platelet counts and quality of life compared to placebo. This drug addresses the root causes of ITP by modulating multiple immune pathways and is already approved in the US, EU, UAE, and UK. Sanofi is also investigating Wayrilz for other rare immune diseases, highlighting its potential beyond ITP.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
